In adults aged 18 years or older, polymyositis can present alongside rapidly progressive interstitial lung disease (RP-ILD) — a severe complication that demands prompt and structured management. This protocol addresses that specific clinical situation.
Adults (≥18 years) with polymyositis and concurrent rapidly progressive interstitial lung disease (RP-ILD) — a comorbidity that directly determines both the urgency and composition of the therapeutic approach.
Induction therapy with high-dose steroids is central to the initial approach, with specific immunosuppressive agents considered alongside — particularly in the setting of RP-ILD. Additional agents may be introduced early, potentially as part of the induction regimen itself.
DOI: 10.1093/rheumatology/keac115
Induction therapy with high dose steroids is to be considered.
The use of ciclosporin or tacrolimus, alongside steroids, is to be considered in patients with RP-ILD.
Cyclophosphamide or rituximab therapy is to be considered early, potentially as part of the induction regimen.
View source ↗